Abbisko Cayman (HKG:2256) stated that Merck has exercised its global commercialization option for pimicotinib (ABSK021) under a 2023 licensing agreement, granting Merck exclusive worldwide rights to the CSF-1R inhibitor, according to a filing with the Hong Kong bourse on Tuesday.
Abbisko received an $85 million exercise fee for its option. This adds to the $70 million upfront payment received earlier, with potential total payments reaching $605.5 million.
The decision follows positive Phase III results for pimicotinib in treating tenosynovial giant cell tumor (TGCT). Abbisko continues advancing its precision oncology pipeline while maintaining collaboration with Merck.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.